Compare Snap Inc (SNAP) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Snap Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Snap Inc trades at $5.31 (market cap $9.18B), while Vertex Pharmaceuticals Incorporated trades at $522.29 (market cap $134.06B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 14.6× Snap Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Snap Inc nearer its low. Which is the better fit depends on your goals.
| SNAP | VRTX | |
|---|---|---|
Market Cap | $9.18B | $134.06B |
Sector | Media | Health |
52-Week High | $9.09 | $557.96 |
52-Week Low | $3.93 | $376.62 |
Enterprise Value | $10.75B | $128.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Snap Inc. (SNAP) trades at $5.43, down 0.73% on the day, with a bullish technical signal driven by moving averages and strong operational cash flow growth. The company reported a net loss of $460.49 million in 2025, but revenue grew to $5.93 billion and losses are narrowing year-over-year. Recent news includes the appointment of a new Chief Commercial Officer and ongoing legal challenges related to youth safety.
The outlook remains cautious; while improving financials and a $7.02 analyst price target suggest upside, persistent net losses, high debt, and regulatory lawsuits pose significant risks. Investor sentiment is mixed amid insider selling and legal overhangs, requiring careful risk assessment for potential investment.
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $522. Fundamentally, 2025 revenue reached $12.0B with a strong net income margin of 35%, though recent quarterly EPS results have been mixed. The company recently completed the acquisition of Crinetics Pharmaceuticals, signaling growth ambitions.
The outlook remains positive given analyst consensus favoring a Buy rating (84%) and a $548.78 price target, implying upside. Key opportunities include revenue growth from new drug launches, while risks involve competitive pressures and earnings volatility. The stock's current valuation at a P/E of 30.8 requires sustained execution to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Snap Inc
Snap, which refers to itself as a camera company, has one of the most popular social networking apps, Snapchat, in developed regions such as North America and Europe. The firm has approximately 158 million daily active users. Snap generates nearly all of its revenue from advertising with 88% coming from the U.S. The firm is headquartered in Venice, California.
Read more on SNAP →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
